NASDAQ · JANX
Janux Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for JANX: Nov 5, 2026
Janux Therapeutics, Inc. Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 7 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.45. The reported EPS for the same quarter last year was $-0.39.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.45 | $-0.04 | $-0.64 | 7 |
| Dec 2026 | $-0.55 | $-0.40 | $-0.70 | 6 |
| Mar 2027 | $-0.58 | $-0.50 | $-0.71 | 4 |
| Jun 2027 | $-0.61 | $-0.51 | $-0.76 | 4 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
BNK Invest · Zacks · RTTNews- BNK Invest · Oct 29, 3:22 PM EDTNotable Thursday Option Activity: SOLS, JANX, UCTTAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Solstice Advanced Materials Inc (Symbol: SOLS), where a total of 17,160 contracts have traded so far, representing approximately 1.7 million underlying shares. That amou
- Zacks · Oct 27, 5:20 PM EDTEnsign Group (ENSG) Beats Q3 Earnings EstimatesEnsign Group (ENSG) delivered earnings and revenue surprises of +4.64% and -0.71%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- BNK Invest · Oct 21, 3:25 PM EDTNotable Wednesday Option Activity: PANW, JANX, ASSTAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Palo Alto Networks, Inc (Symbol: PANW), where a total of 28,758 contracts have traded so far, representing approximately 2.9 million underlying shares. That amounts to a
- Zacks · Sep 30, 6:12 AM EDTIovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains?Iovance Biotherapeutics (IOVA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- Zacks · Sep 16, 5:47 AM EDTThe Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and JanuxProstate cancer awareness spotlights Pfizer's Xtandi, Novartis' Pluvicto and clinical-stage programs from Candel and Janux.
- Zacks · Sep 15, 10:12 AM EDT4 Prostate Cancer Drug Stocks to Watch During Awareness MonthPfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure, with established drugs and clinical or regulatory catalysts.
- RTTNews · Sep 14, 10:12 AM EDTJanux Therapeutics Doses First Patient In Phase 1 Study Of JANX013(RTTNews) – Janux Therapeutics (JANX) announced that the first patient has been dosed in a Phase 1 clinical trial evaluating JANX013, a PSMA-targeted, tumor-activated CD28 co-stimulatory bispecific, in combination with JANX007 in patients with metastatic castration-resistant pros
- Zacks · Aug 21, 10:52 AM EDTJANX Shares Gain 19.1% in 3 Months: Here's What You Need to KnowJanux stock climbs 19.1% in three months as pipeline progress, upcoming catalysts and a strong cash position boost investor confidence.
- Zacks · Aug 6, 5:20 PM EDTJanux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue EstimatesJanux Therapeutics (JANX) delivered earnings and revenue surprises of -34.62% and -72.33%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · May 28, 9:55 AM EDTWall Street Analysts Predict a 155.82% Upside in Janux Therapeutics (JANX): Here's What You Should KnowThe mean of analysts' price targets for Janux Therapeutics (JANX) points to a 155.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- Zacks · May 26, 11:28 AM EDTHere's Why You Should Add JANX Stock to Your Portfolio NowJanux Therapeutics advances multiple oncology and immune therapy programs with key clinical updates, new studies and expanded partnerships with BMY and MRK.
- Zacks · May 7, 7:05 PM EDTJanux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue EstimatesJanux Therapeutics (JANX) delivered earnings and revenue surprises of +21.83% and -75.11%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Janux Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.